In metastatic castration-resistant prostate cancer (mCRPC), germline or somatic homologous recombination repair (HRR) gene mutations can be found in approximately 25% to 30% of tumors.1 Certain HRR mutations have prognostic value and become increasingly relevant as predictive biomarkers for therapies, notably poly(ADP [adenosine diphosphate]-ribose) polymerase inhibitors (PARPi).2,3 Genetic testing can inform treatment decisions for patients with mCRPC and was recommended in national...